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Abstract:  Development  of  efficacious  therapeutic  strategies  to  prevent  and  inhibit  the 
occurrences of restenosis after percutaneous transluminal coronary angioplasty is critical for 
the treatment of cardiovascular diseases. In this study, the feasibility and efficiency of stents 
coated  with  dodecylated  chitosan–plasmid  DNA  nanoparticles  (DCDNPs)  were  evaluated 
as scaffolds for localized and prolonged delivery of reporter genes into the diseased blood 
vessel wall. Dodecylated chitosan–plasmid DNA complexes formed stable positive charged 
nanospheres with mean diameter of approximately 90–180 nm and zeta potential of +28 ± 3 mV . 
As  prepared  DCDNPs  were  spray-coated  on  stents,  a  thin  layer  of  dense  DCDNPs  was 
successfully distributed onto the metal struts of the endovascular stents as demonstrated by 
scanning electron microscopy. The DCDNP stents were characterized for the release kinetics 
of plasmid DNA, and further evaluated for gene delivery and expression both in vitro and in 
vivo. In cell culture, DCDNP stents containing plasmid EGFP-C1 exhibited high level of GFP 
expression in cells grown on the stent surface and along the adjacent area. In animal studies, 
reporter gene activity was observed in the region of the artery in contact with the DCDNP 
stents, but not in adjacent arterial segments or distal organs. The DCDNP stent provides a very 
promising strategy for cardiovascular gene therapy.
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Introduction
Percutaneous transluminal coronary angioplasty (PTCA) and stent implantation are 
the major treatment options for coronary heart diseases. However, the incidence of 
restenosis after PTCA is high,1,2 while in-stent restenosis occurred approximately in 
10%–20% of patients after the stent implantation.3,4 Among the available strategies in 
preventing restenosis, drug-eluting stent (DES) is currently the most commonly used 
in clinical practices.5 DES functions as a scaffold to hold the dilated segment of artery 
open. In addition, the surface of bare-metal stents (BMS) is loaded with drugs, such as 
sirolimus and paclitaxel, which can be released to prevent restenosis by suppressing 
vascular smooth muscle cell proliferation and modulating the inflammatory and 
immune responses at the targeted sites. However, there are also intrinsic shortcomings 
of DES that need to be addressed, such as lack of specific targets in drug effects and 
the cytotoxicity of the drugs on DES. In addition, DES is also susceptible to an event 
known as “late stent thrombosis”, where blood-clotting inside the stent may occur one 
or more years post-stent implantation.6 Therefore, novel strategies to prevent and treat 
restenosis are urgently needed and are of great clinical significance.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Gene therapy is an appealing way to prevent restenosis 
by delivering therapeutic gene into the vascular tissue. Many 
previous studies utilized either intravenous (IV) injection 
or balloon catheter to introduce genes and carriers to blood 
  vessel. Unlike other gene therapies, cardiovascular gene 
therapy encounters the obstacle of specifically delivering 
therapeutic gene to the target site, not the blood circulatory 
system. The use of endovascular stents as scaffolds for 
localized and prolonged delivery of therapeutic genes into 
the diseased blood vessel wall would provide a promising 
solution for gene therapy of in-stent restenosis.7–9 However, 
endovascular stent as a percutaneous gene delivery device 
needs to improve mainly due to insufficient gene loading.
Chitosan (CS) and its derivatives as nonviral gene transfer 
carriers have been extensively studied due to their excellent 
biocompatibility, low immunogenicity, easy preparation, 
large packaging capacity, and high safety.10 They can form 
polyelectrolyte complexes with negatively charged DNA via 
electrostatic interaction, thereby effectively protect DNA 
from nuclease degradation and maintain DNA stability 
under heat conditions. In vitro gene transfection efficiency 
of dodecylated chitosan–plasmid DNA nanoparticles (DCD-
NPs) was evaluated in our previous study, which showed that 
alkylated chitosan (ACS) resulted in a sevenfold increase in 
gene transfection in comparison to that of naked plasmid, 
whereas CS increased the transfection efficiency fourfold.11 
However, there is no report on the effect of stents coated with 
dodecylated chitosan (DCS) gene carrier for the prevention 
and treatment of restenosis.
Herein we report a novel gene delivery approach by 
  successfully tethered gene-loaded DCDNPs on coronary 
stent, which demonstrated high efficiency in plasmid DNA 
delivery and gene expression both in vitro and in vivo. Our 
findings may provide the urgently needed information in 
facilitating the development of novel, safe, and efficient 
vascular stents as gene delivery strategy for the prevention 
and treatment of restenosis.
Materials and methods
Instruments and materials
Zetasizer Nano ZS was obtained from Malvern Instruments 
Ltd (Malvern, Worcestershire, England). Nikon Eclipse 
Ti-U inverted research microscope was obtained from 
Nikon Co (Tokyo, Japan). TD-20/20n luminometer 
was obtained from Turner BioSystems Inc (Sunnyvale, 
CA). CAT X120 homogenizer was obtained from CAT 
Ingenieurbüro M Zipperer GmbH (Staufen, Germany).
Mustang®  316L  stainless  steel  coronary  stents 
(2.5 ± 13 mm) were kindly provided by the Microport 
Medical Co Ltd (Shanghai, China). Dodecylated chitosan 
(50 kDa) was a generous gift from Dr Wenguang Liu 
(Tianjin University, China). The characterization of 
N-alkylated chitosan has been reported previously.12 
The substitution degree (SD) of alkylated chitosan was 
determined by potentiometer titration and calculated to be 
about 20%. Plasmid encoding enhanced green fluorescent 
protein (pEGFP-C1) was purchased from Clontech (Palo 
Alto, CA). A pGL3-control vector (5.3 kb) containing 
SV40 promoter driven luciferase gene was   purchased from 
Promega   (Madison, WI). The plasmids were propagated in 
Escherichia coli and purified by a Qiagen Endofree Plasmid 
Mega Kit (Hilden, Germany). Rat arterial smooth muscle 
cell line (A10) was purchased from American Type Culture 
Collection (ATCC, Gaithersburg, MD). All other chemicals 
were of analytical grade. New Zealand White rabbits (male, 
3.0–3.5 kg) were provided by the Institute of Laboratory 
Animal Science, Chinese Academy of Medical Sciences and 
Peking Union Medical College.
Preparation and characterization  
of the DcDNPs
The DCDNPs were prepared as reported previously.13 Briefly, 
a 0.02% (w/v) solution of dodecylated chitosan in NaAc/HAc 
buffer (pH 5.5) and a solution of DNA (1 µg/µL) in 5 mM 
sodium chloride solution were prewarmed at 55°C for 10 min. 
The DCDNPs were prepared by mixing the two solutions 
and vortexing for 40 s using a CAT X120 homogenizer 
at various charge ratios (amino group to phosphate group 
ratio, N/P). Nanoparticles were batch prepared, sterilized by 
filtering through a 0.22 µm filter with low protein binding, 
and stored at 4°C before use. Particle size, distribution, and 
zeta potential of the nanoparticles were measured on the 
Zetasizer. The final concentration of plasmid DNA in the 
DCDNPs suspension was adjusted to 0.1 µg/µL. Agarose gel 
electrophoretic retardation assay was employed to investigate 
the interaction between the polymers and DNA.
Preparation of DcDNPs-loaded  
stent (NP-stent)
The DCDNPs-loaded stents were prepared under sterile 
conditions as follows. Mustang® 316 L stainless steel stent was 
spray-coated with 10 µL of the DCDNPs solution, and then 
dried at 37°C for 10 min. The procedure was repeated until a 
total of 1 mL DCDNPs suspension was loaded on the surface International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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of a single stent. The dried DCDNPs-treated stents were kept 
sterile at 4°C for later evaluation. The amount of DNA loaded 
on the surface of stent was determined gravimetrically by 
measuring the weight of BMS and DCDNPs-loaded stent. The 
morphologies of bare steel stent and NP-stent were analyzed 
by scanning electron microscopy (SEM).
DNA release kinetics from  
DcDNPs-loaded stent (NP-stent)
The release profile of plasmid DNA from DCDNPs-loaded 
stents was performed as follows. A NP-stent was placed in 
an Eppendorf tube containing phosphate-buffered saline 
(PBS; pH 7.4, 137 mM NaCl) and was incubated at 37°C 
with centrifuge (150 rpm). In triplicate, 150 µL aliquot was 
transferred into a UV-transparent 96-well plate and the 
absorbances at 260 nm were measured by multiplate reader 
at predetermined intervals. After each measurement, the 
media was removed and replaced with fresh PBS buffer. 
The stents were placed back into the tube and returned to 
the incubator.
In vitro gene transfection mediated  
by the NP-stent
NP-stents loaded with pEGFP-C1 plasmid (n = 6) were 
incubated with A10 cell suspension (1 × 106 cells in 
  Dulbecco’s modified Eagle’s medium [DMEM]) at 37°C 
for 1 h, and then transferred into a 35 mm culture dish that 
was preseeded with 1 × 105 A10 cells. The cells were incu-
bated in serum-free media for 5 h followed by the addition 
of fetal bovine serum (FBS) to a final concentration of 10%. 
After 48 h, cells were observed under a Nikon Eclipse Ti-U 
inverted research microscope and fluorescent photographs 
were taken with a Nikon color-cooled digital camera system. 
The same experiments were also performed for dodecylated 
chitosan-coated stents (n = 3) and bare steel stents (n = 3) 
as controls.
In vivo gene transfection mediated  
by the NP-stent
Animal experiment protocols were reviewed and approved 
by the Administrative Committee of Animal Experiments, 
Institute of Biomedical Engineering, Chinese Academy of 
Medical Sciences and Peking Union Medical College. All 
procedures involving the use and care of animals conformed 
to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health.
Two reporter plasmids, pEGFP-C1 and pGL3-control, 
were used to prepare nanoparticles with dodecylated chitosan 
and were evaluated for the feasibility of local gene delivery 
from nanoparticle-coated stents to the target blood vessel 
wall. All animals received aspirin at 40 mg/d dosage 24 h 
before surgery and each day thereafter. Rabbits (n = 8) were 
sedated with intravenous infusion of sodium pentobarbital 
(30 mg/kg). The right carotid artery was implanted with a 
plasmid-loaded NP stent. Similarly, dodecylated chitosan-
coated stents (containing no plasmid DNA) were implanted 
into the right carotid artery of rabbits (n = 6) as control. 
  Surgical procedure, postoperative medication, and treatments 
were performed according to the literature.14 All of the animals 
were sacrificed by an overdose of sodium pentobarbital 7 days 
after the implantation. The arterial samples were retrieved and 
evaluated according to methods published previously.15 The 
stented coronary artery segments were then divided into three 
segments (proximal, medial, and distal). They were embedded 
in Tissue-Tek OCT compound and slides were cut at 5 µm 
thickness for fluorescence and light microscopy examination. 
Frozen sections were also prepared and fixed with 4% 
  paraformaldehyde, counterstained with DAPI, and examined 
under fluorescent microscopy. GFP immunohistochemistry 
experiment was performed as previously described.14 
  Hematoxylin and   eosin-stained sections were examined under 
light microscopy. Samples of the lung, liver, kidney, and distal 
vessel were   harvested and examined for gene expression and 
biodistribution by luciferase assay according to manufacturer’s 
instruction with a Turner TD-20/20n luminometer. Relative 
light units (RLU) were normalized to protein concentration 
in the cell extracts measured by the BCA method.
statistical analysis
The results were presented as mean ± standard deviation. 
Data were analyzed using Statistical Packages for Social 
Sciences program (version 11.0 for Windows; SPSS Inc., 
Chicago, IL). The significance of differences between means 
of experimental groups was determined with Student’s t-test. 
A P-value less than 0.05 was considered significant.
Results and discussion
Preparation and characterization  
of DcDNPs-loaded stents
Dodecylated chitosan–plasmid DNA complexes at various 
N/P ratios were prepared by complex coacervation, which 
yielded stable and positively charged nanoparticles with 
mean diameter of 90–180 nm (Figure 1A) and zeta potential International Journal of Nanomedicine 2010:5
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Figure 1 Mean diameter of dodecylated chitosan–plasmid DNA nanoparticles at different charge ratios (A); size and zeta potential of dodecylated chitosan-plasmid DNA 
nanoparticles (at charge ratio of 2:1) over a 7-day incubation period (B).
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Figure 2 Agarose gel electrophoresis for analysis of cs/DNA (a) or Dcs/DNA 
(b)  complexes.  Lane  1:  plasmid  DNA,  Lane  2:  N/P  =  1:4,  Lane  3:  N/P  =  1:2, 
Lane 4: N/P = 1:1, Lane 5: N/P = 2:1, Lane 6: N/P = 4:1, Lane 7: N/P = 8:1, Lane 8: 
N/P = 10:1.
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of +28 ± 3 mV . Under physiologic condition, the DCDNPs 
did not show significant change in size and zeta potential 
over 1-week incubation (Figure 1B).
As demonstrated in Figure 2, a complete retardation of 
DNA by DCS occurred at charge ratio of 2:1 for CS/DNA 
complex, whereas the dodecylated chitosan fully entrapped 
the DNA at the N/P ratio of 1:1. It suggested that not only 
electrostatic interaction but also hydrophobic interaction con-
tributes to the complex formation between DNA and chitosan 
derivatives. The incorporation of hydrophobic moieties might 
cause a cooperative binding transition of alkylated chitosan.
Previous studies using fluorescent particles showed that a 
size dependency of the transgenic efficacy of nanoparticles,16 
which indicated that the smallest-sized particles (∼110 nm in 
diameter) had the greatest fluorescence intensity within the 
cell in comparison to the larger-sized particles. Other studies 
showed an increase in inflammatory responses with particles 
of 5∼10 µm in diameter and no therapeutic response,   probably 
due to uptake by the macrophages and other immune cells 
rather than smooth muscle cells or endothelial cells.17,18 Hence, 
the current research focused on the dodecylated   chitosan/DNA 
nanoparticles at the charge ratio of 2:1, which is of the smallest 
size in the nanoparticles prepared in the current study.
The stents were spray-coated with DCDNPs solution and 
observed by SEM, with bare steel stent as control. Compared 
with the control stent (Figure 3A and 3B), DCDNPs were 
successfully localized on the surface of endovascular stent 
and a thin layer of dense DCDNPs was observed on the 
metal struts of endovascular stents (Figure 3C). SEM analysis 
revealed that DCDNPs were irregularly coated on the surface 
of the expanded stents as shown at a higher amplification 
(Figure 3D). It was observed that the morphology of the stent 
after the release test (Figure 3E) displayed some differences 
when compared with that before the test, indicating that some 
parts of the coated layer were detached from the stent. These 
changes may be due to the fact that the nanoparticles partially 
detached from the surface of the stent or the complexes formed 
between the polymer and DNA via electrostatic interaction got 
unpacked due to the degradation of the polymeric materials. 
However, the mechanism of the DNA delivery pathway is 
still not completely understood. Further investigation needs 
to be conducted to reveal the mechanism underlying the local 
gene therapy for in-stent restenosis.
Plasmid DNA release profiles from DCDNPs-loaded 
stents in PBS buffer at 37°C were characterized by mea-
suring the absorbance of the solution after each sampling 
interval; the buffer solution was removed and replaced with 
fresh PBS buffer (pH 7.4, 137 mM NaCl) and continued to 
shake at 37°C. Figure 4 is a plot of the accumulated solution 
absorbance at 260 nm versus incubation time. The results 
show that there was an initial burst that occurred during the 
first several hours of incubation, followed by a slight increase 
in DNA release with prolonged incubation. After 7 days, 
DNA release was still detected in the supernatant solution, International Journal of Nanomedicine 2010:5
Figure 3 seM images of DcDNPs-loaded stents. A) bare steel stent; B) bare steel stent at higher amplification; C) NP-stent; D) NP-stent at higher amplification before 
release test; E) NP-stent at higher amplification after release test.
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which strongly suggested that the release of plasmid DNA 
from the stent surface was sustained over a period of up to 
7 days under the experimental conditions.
In vitro gene transfection mediated  
by DcDNP-loaded stents
In order to evaluate the capability of DCDNP-loaded 
stents in delivering genes to target cells, DCDNP-loaded 
stents were incubated with rat arterial smooth muscle cells 
(A10 cells). To our surprise, the NP-stents with plasmid 
pEGFP-C1 in A10 cell culture induced high level of GFP 
expression, particularly in the cells grown on the stent surface 
and along the adjacent area (Figure 5A). In contrast, chitosan-
coated or bare steel stents (without plasmid DNA) showed 
no GFP expression (Figure 5B). Moreover, the NP-stents did 
not show detrimental effects on A10 cell growth.
In vivo gene delivery
In vivo gene delivery efficiency by pEGFP-C1 loaded 
NP-stents was examined by implanting the NP-stents International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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surgically into the rabbit right carotid artery; dodecylated 
chitosan-coated stents (containing no plasmid DNA) were 
implanted as controls. After removing the tissue section 
from rabbit common carotid artery (CCA) at the end of the 
experiment, the samples were embedded in Tissue-Tek OCT 
  compound, followed by fluorescence microscopy analysis of 
the cut slides. The fluorescent GFP expression in CCA sec-
tions was examined and the total number of cells in the same 
region was determined by DAPI staining. It was found that 
approximately 12.3% neointimal cells of CCA were GFP posi-
tive, which could be attributed to gene delivery and expression 
due to the pEGFP-C1 loaded NP-stent (Figure 6).
Furthermore, GFP positive cells were only detected in the 
neointimal layer that was in close contact with the NP-stent 
(Figure 7A). The results from immunohistochemical staining 
using an anti-GFP antibody were also consistent with the 
fluorescent microscopy analysis. In addition, we observed 
no distinct inflammatory response from the samples of stent-
implanted sites (Figure 7B).
As shown from Figure 8, significantly higher level of 
luciferase expression was observed on the arterial samples 
that had been in close contact with NP-stent loaded with 
pGL3-control plasmid in comparison to that of the control 
group. However, luciferase expression was comparable to 
background from the samples of artery 1.5-cm away from 
stented site, contralateral carotid artery, and abdominal artery. 
Trace luciferase expressions were detected from two liver 
specimens, while no luciferase expression was found from 
other specimens from distal organs that included the heart, 
lung, brain, and kidney. The artery and tissue samples from 
the control groups were negative for luciferase expression. 
Therefore, DNA-loaded stent significantly (P , 0.01) 
improved the gene delivery and expression in the stent 
implanted site compared with other sites.
Endovascular stents coated with gene nanoparticles 
may provide a novel means of gene delivery system for 
endovascular gene therapy. However, currently there is no 
effective gene-coated stent that can safely and   specifically 
deliver target therapeutic genes to the cardiovascular 
  target cells and not be lost in the blood circulation system. 
Moreover, it remains technically challenging to evenly 
and completely coat the stent with target genes. Alkylated 
  chitosan could improve the thermal stability of DNA, protect 
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Figure 4 Plasmid DNA release profile from DCDNPs-loaded stents.
Figure 5 gFP expressions in A10 cells incubated with pegFP-c1 loaded NP-stents. 
A) pegFP-c1-loaded NP-stents; B) dodecylated chitosan-coating stent (no plasmid 
DNA) (FITc, 100×).
Figure 6 rabbit ccA results demonstrating cells expressing gFP mediated by 
pegFP-c1-loaded NP stents in vivo.
Figure  7  rabbit  ccA  results  demonstrating  gFP  transduction  in  arterial  wall: 
A)  example  of  gFP  expression  following  NP-stent  implanting  (FITc;  50×);  B) 
Immunohistochemical confirmation of GFP expression (immunoperocidase; 50×).International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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DNA from enzyme degradation by DNase, and enhance gene 
transfection efficiency. It is proposed that the higher trans-
fection efficiency of ACS is attributed to the increased entry 
into cells facilitated by hydrophobic interactions and easier 
unpacking of DNA from ACS carriers due to the weakening 
of electrostatic attractions between DNA and ACS.11 In this 
study, we combined the advantages of DCDNPs as a low 
toxic and high efficient nonviral vector with the inherent 
feature of coronary stent and accomplished effective intra-
vascular delivery of plasmid DNA.
It was estimated that under in vivo conditions, a small 
amount of DCDNPs coated on a stent surface could be 
washed off by blood flow into the blood circulation and 
absorbed by the reticuloendothelial system, which is 
mainly distributed in organs such as liver, spleen, and 
bone marrow. Reticuloendothelial system functions to 
absorb microparticles and nanoparticles by phagocytosis. 
Therefore, a low level of luciferase and GFP expression 
was observed in liver and this result is consistent with 
previous results showing that intravenous injection of 
chitosan nanoparticles often leads to liver aggregation.19 
Since chitosan itself is nontoxic and only a small amount of 
chitosan reaches the liver, the effect is negligible. Overall, 
we observed no significant side effects. For future studies, 
we will explore novel strategies to covalently tether DCD-
NPs onto metal stent surface in order to further improve 
the local delivery and expression efficiency. The use of 
DCDNPs has demonstrated to be an attractive route for 
improving both the safety and efficiency of therapeutic 
gene delivery.
Conclusion
In this study, we investigated the feasibility and efficiency of 
DCDNPs-coated stent as scaffolds for localized and   prolonged 
delivery of reporter genes into a diseased blood vessel wall. 
We successfully demonstrated that bare metal stents spray-
coated with DCDNPs were able to continuously release target 
DNAs. This facilitated the delivery of   therapeutic genes into 
the targeted artery wall cells and resulted in remarkable local 
gene transfection and   expression both in vitro and in vivo. 
The results demonstrate a significant progress in the local 
delivery of plasmid DNA into intravascular tissue for gene 
therapy of restenosis. In addition to the high gene trans-
fection efficiency, the DCDNPs-stent system also has the 
advantages of easy fabrication, biocompatibility, and low 
immunogenicity. This system could be a very promising 
cardiovascular gene therapy strategy for diseases such as 
in-stent restenosis.
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